Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 2/20 | 0.46 |
| ▸ | GAK | O14976 | 6/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.43 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.43 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.43 |
| ▸ | EPHA8 | P29322 | 1/20 | 0.43 |
| ▸ | TXK | P42681 | 1/20 | 0.43 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | STK16 | O75716 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.42 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9998100 | 0.79 | ABCG2 (0.45) | TRPA1CNR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8272301 | 0.78 | TRPA1 (0.57) | GAKIDO1TDO2TRPA1CYP1A2 | |
| SCHEMBL12335848 | 0.76 | MAPT (0.43) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL31559378 | 0.75 | PLAU (0.47) | GAKRIPK2NLKEPHB6ABL1 | |
| SCHEMBL2671619 | 0.75 | PLAU (0.47) | GAKRIPK2NLKEPHB6ABL1 | |
| SCHEMBL9998301 | 0.75 | MAPK1 (0.43) | TRPA1CNR2CYP3A4MAPTNOS3 | |
| SCHEMBL26932395 | 0.75 | MAPT (0.43) | RIPK2ABL1TRPA1CYP1A2CYP3A4 | |
| SCHEMBL8272298 | 0.75 | MAPT (0.46) | MAT2AGAKRIPK2NLKCOQ8A | |
| SCHEMBL9999465 | 0.75 | NOS3 (0.52) | MAT2ACNR2NOS3NOS2SCN9A | |
| SCHEMBL2240307 | 0.73 | TRPA1 (0.54) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582692-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-22 | — | — | EP | disclosed |
| EP-2582692-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-22 | — | — | EP | disclosed |
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-20130310365-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICAL NV (BE) | 2013-11-21 | — | — | US | disclosed |
| US-20130310365-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICAL NV (BE) | 2013-11-21 | — | — | US | disclosed |
| US-8518969-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-27 | — | — | US | disclosed |
| US-8518969-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-27 | — | — | US | disclosed |
| US-8518969-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-27 | — | — | US | disclosed |
| EP-2582692-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011159854-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159854-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-22 | — | — | WO | disclosed |
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTAICA N.V. (BE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTAICA N.V. (BE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTAICA N.V. (BE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | MAT2A 1467/4885GAK 2778/4885RIPK2 2073/4885 |
| US-20130310365-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | MAT2A 1467/4885GAK 2778/4885RIPK2 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.